Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients
Eli Lilly and Co. (NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo (selpercatinib).
The trial demonstrated a highly statistically significant improvement in event-free survival for patients with early-stage non-small cell lung cancer.
Lung Cancer Trial Shows Benefit
The LIBRETTO-432 trial results showed that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer.
This trial is the first randomized Phase 3 study evaluating a selective RET kinase inhibitor as adjuvant therapy, reinforcing the value of genomic testing in cancer treatment.
In addition, the overall safety profile of selpercatinib was consistent with previous studies, and detailed results are expected to be presented at an upcoming medical congress. The trial enrolled 151 patients who received either selpercatinib or placebo, marking a significant step in the treatment of early-stage lung cancer.
The broader market experienced a mixed day on the previous trading day, with the S&P 500 futures down 0.4% while the Healthcare sector remained unchanged.
Eli Lilly’s gains come as the Healthcare sector is currently ranked 8 out of 11 sectors, indicating mid-tier performance.
Technical Analysis
Eli Lilly shares have increased 21.33% over the past 12 months, reflecting a strong upward trend. Currently, the stock is trading above its key support level of $1033.50 and is positioned closer to its 52-week highs than lows, suggesting continued strength in its price action.
The RSI is at a neutral level, indicating that the stock is neither overbought nor oversold at this time. Meanwhile, the MACD is also neutral, suggesting a balanced momentum without strong bullish or bearish pressure.
The combination of neutral RSI and MACD suggests mixed momentum, indicating that traders should watch for potential breakout or reversal signals in the near term.
- Key Resistance: $1088.50
- Key Support: $1033.50
Analyst Consensus & Recent Actions:
The stock carries a Buy Rating with an average price target of $1141.70. Recent analyst moves include:
- Deutsche Bank: Buy (Raises Target to $1285)
- JP Morgan: Overweight (Raises Target to $1300)
- Cantor Fitzgerald: Overweight (Raises Target to $1205)
Benzinga Edge Rankings
The Benzinga Edge scorecard for Eli Lilly highlights its strengths and weaknesses compared to the broader market:
- Value Rank: 3.49 — Indicates the stock is trading at a premium relative to peers.
- Quality Rank: 90.9 — Suggests a strong balance sheet and operational efficiency.
- Momentum Rank: 84.91 — Reflects strong price performance relative to the market.
The Verdict: Eli Lilly’s Benzinga Edge signal reveals a strong momentum score, indicating that the stock is outperforming the broader market. However, the low value rank suggests that investors should be cautious of potential overvaluation.
Top ETF Exposure
- Capital Group Dividend Value ETF (NYSE:CGDV): 6.06% Weight
- Simplify Health Care ETF (NYSE:PINK): 7.46% Weight
- Dana Unconstrained Equity ETF (NYSE:DUNK): 7.58% Weight
LLY Price Action: Eli Lilly and Co shares were up 0.52% at $1045.41 during premarket trading on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Crypto prices
More
